Literature DB >> 29688327

Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.

Kwok-Ho Lam1, Stefan Sikorra2, Jasmin Weisemann3, Hannah Maatsch2, Kay Perry4, Andreas Rummel3, Thomas Binz2, Rongsheng Jin1.   

Abstract

The extreme toxicity of botulinum neurotoxins (BoNTs) relies on their specific cleavage of SNARE proteins, which eventually leads to muscle paralysis. One newly identified mosaic toxin, BoNT/HA (aka H or FA), cleaves VAMP-2 at a unique position between residues L54 and E55, but the molecular basis underlying VAMP-2 recognition of BoNT/HA remains poorly characterized. Here, we report a ∼2.09 Å resolution crystal structure of the light chain protease domain of BoNT/HA (LC/HA). Structural comparison between LC/HA and LC of BoNT/F1 (LC/F1) reveals distinctive hydrophobic and electrostatic features near the active sites, which may explain their different VAMP-2 cleavage sites. When compared to BoNT/F5 that cleaves VAMP-2 at the same site as BoNT/HA, LC/HA displays higher affinity for VAMP-2, which could be caused by their different surface charge properties surrounding a VAMP-2 exosite-binding cleft. Furthermore, systematic mutagenesis studies on VAMP-2 and structural modeling demonstrate that residues R47 to K59 spanning the cleavage site in VAMP-2 may adopt a novel extended conformation when interacting with LC/HA and LC/F5. Taken together, our structure provides new insights into substrate recognition of BoNT/HA and paves the way for rational design of small molecule or peptide inhibitors against LC/HA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29688327      PMCID: PMC5961070          DOI: 10.1093/femspd/fty044

Source DB:  PubMed          Journal:  Pathog Dis        ISSN: 2049-632X            Impact factor:   3.166


  50 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.

Authors:  Joseph W Arndt; Qing Chai; Todd Christian; Raymond C Stevens
Journal:  Biochemistry       Date:  2006-03-14       Impact factor: 3.162

3.  Molecular characterization of a novel botulinum neurotoxin type H gene.

Authors:  Nir Dover; Jason R Barash; Karen K Hill; Gary Xie; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

4.  Molecular mechanisms of substrate recognition and specificity of botulinum neurotoxin serotype F.

Authors:  Sheng Chen; Hoi Ying Wan
Journal:  Biochem J       Date:  2011-01-15       Impact factor: 3.857

Review 5.  Neurotoxins affecting neuroexocytosis.

Authors:  G Schiavo; M Matteoli; C Montecucco
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

6.  SNARE motif and neurotoxins.

Authors:  O Rossetto; G Schiavo; C Montecucco; B Poulain; F Deloye; L Lozzi; C C Shone
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

Review 7.  Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature.

Authors:  Michael W Peck; Theresa J Smith; Fabrizio Anniballi; John W Austin; Luca Bano; Marite Bradshaw; Paula Cuervo; Luisa W Cheng; Yagmur Derman; Brigitte G Dorner; Audrey Fisher; Karen K Hill; Suzanne R Kalb; Hannu Korkeala; Miia Lindström; Florigio Lista; Carolina Lúquez; Christelle Mazuet; Marco Pirazzini; Michel R Popoff; Ornella Rossetto; Andreas Rummel; Dorothea Sesardic; Bal Ram Singh; Sandra C Stringer
Journal:  Toxins (Basel)       Date:  2017-01-18       Impact factor: 4.546

Review 8.  The evolving field of biodefence: therapeutic developments and diagnostics.

Authors:  James C Burnett; Erik A Henchal; Alan L Schmaljohn; Sina Bavari
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate.

Authors:  Jorge E Zuniga; James J Schmidt; Timothy Fenn; James C Burnett; Demet Araç; Rick Gussio; Robert G Stafford; Shirin S Badie; Sina Bavari; Axel T Brunger
Journal:  Structure       Date:  2008-10-08       Impact factor: 5.006

View more
  4 in total

Review 1.  Engineering of Botulinum Neurotoxins for Biomedical Applications.

Authors:  Robert P Webb
Journal:  Toxins (Basel)       Date:  2018-06-06       Impact factor: 4.546

Review 2.  Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity.

Authors:  Elena Fonfria; Mark Elliott; Matthew Beard; John A Chaddock; Johannes Krupp
Journal:  Toxins (Basel)       Date:  2018-07-04       Impact factor: 4.546

3.  The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA.

Authors:  Yongfeng Fan; Jason R Barash; Fraser Conrad; Jianlong Lou; Christina Tam; Luisa W Cheng; Stephen S Arnon; James D Marks
Journal:  Toxins (Basel)       Date:  2019-12-20       Impact factor: 4.546

4.  Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B.

Authors:  Takuhiro Matsumura; Sho Amatsu; Ryo Misaki; Masahiro Yutani; Anariwa Du; Tomoko Kohda; Kazuhito Fujiyama; Kazuyoshi Ikuta; Yukako Fujinaga
Journal:  Toxins (Basel)       Date:  2020-05-07       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.